Introduction
patients with chronic liver disease [5, 6] . The [7] [8] [9] [10] , and therefore represents a novel therapeutic avenue to combat several angiogenesis-related diseases [11, 12] . The angioinhibitory properties of octreotide are predominantly mediated by the high affinity somatostatin subtype 2 receptor (SSTR2) [13] . The possible anti-angiogenic effects of octreotide have not been characterized in portal hypertension as yet. Hence, in the present study, we determined the role of octreotide as an inhibitor of angiogenesis in portal hypertensive rats.
Materials and methods

Materials
Octreotide was purchased from Novartis (Basel, Switzerland [14] . 
Animals and treatments
Portal hypertension was induced in male Sprague-Dawley rats (300-350 g body weight) by partial portal vein ligation (PPVL) as previously described
Measurement of vascular areas
Statistics
All data were expressed as mean ± SEM. Unpaired Student's t-test and ANOVA
were used for statistical analysis and P < 0.05 was accepted as significant.
Results
Effects on splanchnic neovascularization and VEGF expression. Figure 2 , the mesentery from portal hypertensive rats treated with vehicle was intensely neovascularized both at day 4 and at day 7 after PPVL. This increased vascular area was significantly reduced, by 64%, after
Fig. 1 Expression of VEGF and CD31 in the intestine of portal hypertensive rats treated with octreotide or vehicle during 4 or 7 days after induction of portal hypertension by partial portal vein ligation (PPVL). Representative blots for VEGF, CD31 and the housekeeping protein GAPDH are shown at the left and quantification of expression normalized to GAPDH and expressed as arbitrary units is shown at the right. treatment with octreotide for a 4-day period, but not when the treatment took place during 7 days. Therefore, these findings further confirmed those observed using the western blot technique.
Effects on portosystemic collateral circulation
There was a tendency for the extent of collateral vessel formation to be lower (16% decrease) in portal hypertensive rats treated with octreotide from the day of PPVL to day 4 th than in vehicle-treated portal hypertensive rats, but this change was not statistically significant (P = 0.18; Fig. 3 ). This tendency was not observed when treatment with octreotide was started immediately after PPVL and terminated 7 days later (P = 0.57; Fig. 3 ).
Effects on SSTR2 expression
We also measured the expression of the SSTR2 receptor, which predominantly mediates the anti-angiogenic effects of octreotide [13] . SSTR2 protein was expressed in the intestine from shamoperated rats. Remarkably, after induction of portal hypertension, there was a progressive decline of SSTR2 expression over time, with a 40% decrease at day 4 after PPVL (P = 0. 19 ) and up to a 78% reduction at day 7 after PPVL (P < 0.01), compared with sham-operated rats (Fig. 4) . Treatment with octreotide during either 4 or 7 days from PPVL did not significantly modify SSTR2 expression compared with the corresponding vehicle-treated groups (Fig. 4) .
Hemodynamic effects
Octreotide treatment during 4 days, starting immediately after PPVL, caused no significant changes in MAP, SMABF and SMAR (Fig. 5) , but octreotide significantly decreased PP by 15% (P < 0.05; Fig. 4 (Fig. 6) 
. Interestingly, the intestinal expression of HO-1 increased markedly and significantly after octreotide treatment in portal hypertensive rats, both in the 4-days treatment group (148% increase; P < 0.05) and in the 7-days treatment group (113% increase; P < 0.01) compared with vehicle-treated portal
hypertensive rats (Fig. 6 ). 
Discussion
The present study demonstrates that, early after the induction of portal hypertension, the somatostatin analogue octreotide significantly decreases the extent of splanchnic neovascularization as well as the expression of the growth factor VEGF in splanchnic
Fig. 6 Expression of eNOS and HO-1 in the intestine of portal hypertensive rats treated with octreotide or vehicle during 4 or 7 days after induction of portal hypertension by PPVL. Representative blots for eNOS, HO-1 and the housekeeping protein GAPDH are shown at the left and quantification of expression normalized to GAPDH and expressed as arbitrary units is shown at the right.
The mechanism by which SSTR2 expression diminishes during the evolution of portal hypertension is at present unknown. Interestingly, several lines of evidence suggest that SSTR2 is uniquely down-regulated in endothelial cells during angiogenesis [10] [11] [12] . Thus, it has been previously demonstrated that SSTR2 is strongly expressed in normal pancreas, whereas expression of this receptor is frequently lost in pancreatic tumors [16, 17] . In addition, normal human retina displays strong SSTR2 expression, whereas in eyes with late stages of age-related maculopathy, characterized by choroidal neovascularization, SSTR2 is expressed at low levels or not expressed at all [18] . In our present study, SSTR2 was progressively down-regulated in the intestinal mucosa upon the onset of angiogenic signaling in the splanchnic vasculature of portal hypertensive rats, suggesting that angiogenesis could trigger SSTR2 down-regulation in this experimental model. By contrast, other studies have found that a large variety of tumors are rich in SSTR2 [5] . The reason for this discrepancy is unclear but may be due in part to tissue-specific differences in the expression of somatostatin receptors.
In [19] [20] [21] . HO-1 activity plays an important role in cellular protection against oxidative injury [13] . This is related to the fact that this enzymatic system breaks down heme, thereby mitigating the hazardous cellular effects of this pro-oxidant. In addition, HO activity produces biliverdin, which is converted to bilirubin by the action of biliverdin reductase. Both biliverdin and bilirubin are potent antioxidants.
the present study, we also determined the effects of octreotide on the formation of portosystemic collateral vessels, which is, in part, a VEGF-dependent angiogenic process in portal hypertension. Octreotide decreased the extent of collateral formation by 16% after 4 days of treatment compared with vehicle-treated portal hypertensive rats, but the difference did not reach statistical significance (P = 0.18). After 7 days of treatment
Moreover, the enzymatic HO activity generates carbon monoxide (CO), which in addition of being a potent vasodilator also has antiinflammatory properties [21] . Recently, we have demonstrated that HO-1 up-regulation constitutes an important antioxidant mechanism in portal hypertensive rats [22, 23] 
